Seems to me like they have a simple and brilliant strategy which happens to maximize current share holder value. Focus on short duration improvement for advanced AD will get this drug to market fast and cheap. On Phase 2b data FDA should have no issue approving Phase 3 at 20 m for either 13 or 26 weeks, either way they will have a drug to market in about a year. With 25 mil in cash and 1 mil shares in reserve seems like they have all they need to get it done. Even a deal in place to produce the drug.
Once you have that massive cash flow, other applications and studies can follow.
For a company accused of pump and dump, there doesn't seem to be much pump and good PR coming from the company. Possible reason could be that they have the cash they need for Phase 3 and don't much care about current SP.
News 
Market Data 
Discover 
